Version history

{
  "session_id": "sess_SDA-2026-04-11-sda-2026-04-01-gap-006",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "support",
  "content": "**Key Clinical Programs:**\n- **BIIB078 (Biogen):** Antisense oligonucleotide targeting C9orf72 - Phase 1 completed but terminated in extension study\n- **WVE-004 (Wave Life Sciences):** Allele-selective antisense - Phase 1 terminated\n- **PBFT02 (Passage Bio):** Gene therapy approach - Phase 1 ongoing\n\n**Market Reality:**\n- Multiple failed programs suggest high difficulty\n- C9orf72 represents ~40% of familial ALS (~2,000-3,000 patients globally)\n- Clear unmet need with no approved therapies\n\n**Cost/Timeline:** $100-200M, 8-10 years (peptide advantages: faster than small molecules)\n\n### Hypothesis 5: G4C2 RNA Decoy Therapeutics\n**Druggability Score: 4/10**\n\n**Modality Analysis:**\n- **Platform:** Antisense oligonucleotides (ASOs) or competing decoy RNAs\n- **Precedent:** Multiple failed ASO programs (BIIB078, WVE-004) suggest challenges\n- **Delivery:** Intrathecal administration required for CNS penetration\n\n**Why Previous Efforts Failed:**\n- Insufficient target engagement\n- Dose-limiting toxicities\n- Complex RNA secondary structures (G-quadruplexes) resist binding\n\n**Cost/Timeline:** $150-300M, 10-12 years\n\n### Hypothesis 6: Phase Transition Kinetics Modulators\n**Druggability Score: 2/10**\n\n**Fundamental Issues:**\n- No precedent for \"kinetic modulators\" of phase separation\n- Unclear what chemical matter would achieve this\n- Measurement of kinetics in vivo is essentially impossible\n\n**Commercial Reality:**\n- No companies pursuing this specific approach\n- Academic concept without translation path\n- Would require entirely new platform development\n\n**Cost/Timeline:** $500M+, 15+ years (research-stage concept)\n\n### Hypothesis 7: Bi-functional Molecules\n**Druggability Score: 1/10**\n\n**Chemical Reality:**\n- Bi-functional molecules typically fail due to competing pharmacological requirements\n- Nuclear transport proteins and IDRs require incompatible molecular properties\n- No successful precedent for this type of bifunctional approach\n\n**Development Challenges:**\n- Molecular weight likely >800 Da (poor CNS penetration)\n- Competing structure-activity relationships\n- Increased off-target risks\n\n**Cost/Timeline:** $300-500M, 12-15 years (high failure risk)\n\n## OVERALL FEASIBILITY RANKING\n\n1. **Hypothesis 4 (DPR Inhibitors): 7/10**\n   - Clear molecular target\n   - Defined patient population\n   - Precedent for peptide CNS drugs\n   - **Recommended investment:** $100-200M\n\n2. **Hypothesis 1 (Nuclear Import Enhancers): 6/10**\n   - Druggable target class\n   - Novel mechanism\n   - **Risk:** Selectivity challenges\n   - **Recommended investment:** $75-150M\n\n3. **Hypothesis 5 (RNA Decoys): 4/10**\n   - Multiple failed precedents\n   - Technical delivery challenges\n   - **Investment:** High risk/high reward\n\n4. **Hypothesis 3 (Organelle Stabilizers): 4/10**\n   - Emerging target class\n   - Dewpoint acquisition validates space\n   - **Risk:** IDR druggability\n\n5. **Hypothesis 2 (RNA Editing): 3/10**\n   - Ultra-orphan market\n   - Technical platform challenges\n\n6. **Hypothesis 6 (Kinetics Modulators): 2/10**\n   - No clear path forward\n   - Academic concept only\n\n7. **Hypothesis 7 (Bi-functional): 1/10**\n   - Chemically implausible\n   - No precedent for success\n\n## RECOMMENDATION\n\n**Priority Investment:** Focus on Hypothesis 4 (DPR Inhibitors) with a backup program on Hypothesis 1 (Nuclear Import Enhancers). The C9orf72 space has clear unmet need despite previous failures, and peptide-based approaches may overcome the delivery issues that plagued ASO programs.",
  "tokens_used": "872",
  "persona_id": "persona-domain_expert"
}